PharmGKB summary
Tóm tắt
Từ khóa
Tài liệu tham khảo
Boocock, 2000, Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts., Carcinogenesis, 21, 1851, 10.1093/carcin/21.10.1851
Desta, 2004, Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6., J Pharmacol Exp Ther, 310, 1062, 10.1124/jpet.104.065607
Goetz, 2003, A hot flash on tamoxifen metabolism., J Natl Cancer Inst, 95, 1734, 10.1093/jnci/djg129
Henry, 2008, Drug interactions and pharmacogenomics in the treatment of breast cancer and depression., Am J Psychiatry, 165, 1251, 10.1176/appi.ajp.2008.08040482
Osborne, 1998, Tamoxifen in the treatment of breast cancer., N Engl J Med, 339, 1609, 10.1056/NEJM199811263392207
Jordan, 1975, Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor., Eur J Cancer, 11, 205, 10.1016/0014-2964(75)90119-X
Lippman, 1975, Oestrogen-responsive human breast cancer in long term tissue culture., Nature, 256, 592, 10.1038/256592a0
Allen, 1980, Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships., Br J Pharmacol, 71, 83, 10.1111/j.1476-5381.1980.tb10912.x
Jordan, 1977, A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity., J Endocrinol, 75, 305, 10.1677/joe.0.0750305
Jordan, 2003, Tamoxifen: a most unlikely pioneering medicine., Nat Rev Drug Discov, 2, 205, 10.1038/nrd1031
Lu, 2012, Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer., Breast Cancer Res Treat, 131, 473, 10.1007/s10549-011-1428-z
Lu, 2012, The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents., Breast Cancer Res Treat, 133, 99, 10.1007/s10549-011-1699-4
Kiyotani, 2012, Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters., Drug Metab Pharmacokinet, 27, 122, 10.2133/dmpk.DMPK-11-RV-084
Lien, 1988, Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile., Cancer Res, 48, 2304
Wu, 2009, The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells., Cancer Res, 69, 1722, 10.1158/0008-5472.CAN-08-3933
Parte, 2005, Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin., Drug Metab Dispos, 33, 1446, 10.1124/dmd.104.000802
Iusuf, 2011, P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration., J Pharmacol Exp Ther, 337, 710, 10.1124/jpet.110.178301
Teft, 2011, Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1)., Drug Metab Dispos, 39, 558, 10.1124/dmd.110.036160
Falany, 2006, Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases., Drug Metab Dispos, 34, 361, 10.1124/dmd.105.006551
Hertz, 2012, Tamoxifen and CYP2D6: a contradiction of data., Oncologist, 17, 620, 10.1634/theoncologist.2011-0418
Lim, 2007, Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer., J Clin Oncol, 25, 3837, 10.1200/JCO.2007.11.4850
Wegman, 2007, Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer., Breast Cancer Res, 9, R7, 10.1186/bcr1640
Goldberg, 2012, Experts claim errors in breast cancer study, demand retraction of practice-changing paper., Cancer Lett, 38, 1